[ET Net News Agency, 21 February 2024] HSBC Global Research lowered the target price
for Fosun Pharma (02196) to HKD15 from HKD20 and maintained the "hold" rating.
The research house said it expects revenue growth in the low teens over 2024-25e.
Earnings growth could still be pressured by the biosimilar VBP and overseas business
expansion. (RC)